To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2018 News Releases

About RSS

Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer (pdf 531KB)

February 6, 2018

Printer-friendly version


Main Text end
Local Navigation
Local Navigation end
Related Links